| SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES WERE EXCLUDED FROM CALCULATION OF DILUTED NET LOSS PER SHARE |
The
following potentially dilutive securities were excluded from the calculation of diluted net loss per share because the effects were anti-dilutive
based on the application of the treasury stock method and because the Company incurred net losses during the period:
SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES WERE EXCLUDED FROM CALCULATION OF DILUTED NET LOSS PER SHARE
| | |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| | |
For the Six Months Ended
June 30, | | |
For the Three Months Ended
June 30, | |
| | |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| Options to purchase shares of common stock | |
| 120,000 | | |
| 120,000 | | |
| 120,000 | | |
| 120,000 | |
| Warrants to purchase shares of common stock granted on February 14, 2021 to CreoMed, Inc.* | |
| 400,000 | | |
| 400,000 | | |
| 400,000 | | |
| 400,000 | |
| Warrants to purchase shares of common stock granted on March 16, 2021 to Demir Bingol* | |
| 300,000 | | |
| 300,000 | | |
| 300,000 | | |
| 300,000 | |
| Warrants to purchase shares of common stock granted on April 1, 2022 to CreoMed, Inc. | |
| 400,000 | | |
| 400,000 | | |
| 400,000 | | |
| 400,000 | |
| Warrants to purchase shares of common stock granted on various dates in fiscal year 2022 and 2025 | |
| 4,960,000 | | |
| 490,000 | | |
| 4,960,000 | | |
| 490,000 | |
| Total potentially dilutive shares | |
| 6,180,000 | | |
| 1,710,000 | | |
| 6,180,000 | | |
| 1,710,000 | |
| * |
The Company has cancelled
and regranted these warrants to purchase 1,098,830 shares (698,830 warrants issued to the Ahmet Demir Bingol and 400,000 to CreoMed
Inc.) of the Company’s common stock on June 29, 2021 in conjunction with the share exchange agreement. |
|
| SCHEDULE OF COMPUTATION OF BASIC AND DILUTED NET INCOME PER SHARE |
The
following table sets forth the computation of basic and diluted net income per share:
SCHEDULE OF COMPUTATION OF BASIC AND DILUTED NET INCOME PER SHARE
| | |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| | |
For the Six Months Ended June 30, | | |
For the Three Months Ended June 30, | |
| | |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| | |
| | |
| | |
| | |
| |
| Net loss attributable to the common stockholders | |
$ | (198,549 | ) | |
$ | (47,388 | ) | |
$ | (95,228 | ) | |
$ | (31,228 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Basic weighted average outstanding shares of common stock | |
| 24,667,148 | | |
| 20,082,807 | | |
| 26,740,499 | | |
| 20,439,950 | |
| Dilutive effect of options and warrants | |
| - | | |
| - | | |
| - | | |
| - | |
| Diluted weighted average common stock and common stock equivalents | |
| 24,667,148 | | |
| 20,082,807 | | |
| 26,740,499 | | |
| 20,439,950 | |
| | |
| | | |
| | | |
| | | |
| | |
| Loss per share: | |
| | | |
| | | |
| | | |
| | |
| Basic and diluted | |
$ | (0.01 | ) | |
$ | (0.00 | ) | |
$ | (0.00 | ) | |
$ | (0.00 | ) |
|